CN109310634A - 用于治疗前段眼部疾病的持续输送他克莫司的纳米脂质体 - Google Patents
用于治疗前段眼部疾病的持续输送他克莫司的纳米脂质体 Download PDFInfo
- Publication number
- CN109310634A CN109310634A CN201780024828.2A CN201780024828A CN109310634A CN 109310634 A CN109310634 A CN 109310634A CN 201780024828 A CN201780024828 A CN 201780024828A CN 109310634 A CN109310634 A CN 109310634A
- Authority
- CN
- China
- Prior art keywords
- nano liposomes
- unsaturated
- phosphocholine
- variety
- tacrolimus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (31)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201603094P | 2016-04-19 | ||
SG10201603094P | 2016-04-19 | ||
PCT/SG2017/050216 WO2017184080A1 (en) | 2016-04-19 | 2017-04-19 | Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109310634A true CN109310634A (zh) | 2019-02-05 |
CN109310634B CN109310634B (zh) | 2022-05-31 |
Family
ID=60116958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780024828.2A Active CN109310634B (zh) | 2016-04-19 | 2017-04-19 | 用于治疗前段眼部疾病的持续输送他克莫司的纳米脂质体 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11672784B2 (zh) |
EP (1) | EP3445334A4 (zh) |
JP (1) | JP7186093B2 (zh) |
CN (1) | CN109310634B (zh) |
SG (2) | SG10202010303UA (zh) |
WO (1) | WO2017184080A1 (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
US20020013340A1 (en) * | 2000-02-18 | 2002-01-31 | Peyman Gholam A. | Treatment of ocular disease |
CN1342075A (zh) * | 1999-03-11 | 2002-03-27 | 藤泽药品工业株式会社 | 脂质体制剂 |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
EP2058009A1 (en) * | 2006-08-31 | 2009-05-13 | Astellas Pharma Inc. | Reverse targeting lipid vesicle |
CA2781529A1 (en) * | 2009-09-23 | 2011-03-31 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
US20110212167A1 (en) * | 2008-09-27 | 2011-09-01 | Jina Pharmaceuticals, Inc. | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
CN102202694A (zh) * | 2008-10-07 | 2011-09-28 | 博莱科瑞士股份有限公司 | 包含抗-聚合物抗体的靶向构建体和结合它们的脂质体或微泡 |
CN103142468A (zh) * | 2012-12-28 | 2013-06-12 | 中山大学 | 用于眼角膜移植的他克莫司眼用剂及其制备方法 |
US20130216606A1 (en) * | 2010-08-12 | 2013-08-22 | Singapore Health Services Pte Ltd | Liposomal formulation for ocular drug delivery |
WO2015061449A1 (en) * | 2013-10-22 | 2015-04-30 | Lipella Pharmaceuticals, Inc. | Delivery of agents using metastable liposomes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1127955C (zh) * | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
US20040224010A1 (en) * | 2002-11-15 | 2004-11-11 | Optime Therapeutics, Inc. | Ophthalmic liposome compositions and uses thereof |
EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
-
2017
- 2017-04-19 EP EP17786259.6A patent/EP3445334A4/en active Pending
- 2017-04-19 WO PCT/SG2017/050216 patent/WO2017184080A1/en active Application Filing
- 2017-04-19 SG SG10202010303UA patent/SG10202010303UA/en unknown
- 2017-04-19 JP JP2018554752A patent/JP7186093B2/ja active Active
- 2017-04-19 US US16/094,827 patent/US11672784B2/en active Active
- 2017-04-19 SG SG11201809154UA patent/SG11201809154UA/en unknown
- 2017-04-19 CN CN201780024828.2A patent/CN109310634B/zh active Active
-
2023
- 2023-04-27 US US18/308,557 patent/US20230263780A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
CN1342075A (zh) * | 1999-03-11 | 2002-03-27 | 藤泽药品工业株式会社 | 脂质体制剂 |
US20020013340A1 (en) * | 2000-02-18 | 2002-01-31 | Peyman Gholam A. | Treatment of ocular disease |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
EP2058009A1 (en) * | 2006-08-31 | 2009-05-13 | Astellas Pharma Inc. | Reverse targeting lipid vesicle |
US20110212167A1 (en) * | 2008-09-27 | 2011-09-01 | Jina Pharmaceuticals, Inc. | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
CN102202694A (zh) * | 2008-10-07 | 2011-09-28 | 博莱科瑞士股份有限公司 | 包含抗-聚合物抗体的靶向构建体和结合它们的脂质体或微泡 |
CA2781529A1 (en) * | 2009-09-23 | 2011-03-31 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
US20130216606A1 (en) * | 2010-08-12 | 2013-08-22 | Singapore Health Services Pte Ltd | Liposomal formulation for ocular drug delivery |
CN103142468A (zh) * | 2012-12-28 | 2013-06-12 | 中山大学 | 用于眼角膜移植的他克莫司眼用剂及其制备方法 |
WO2015061449A1 (en) * | 2013-10-22 | 2015-04-30 | Lipella Pharmaceuticals, Inc. | Delivery of agents using metastable liposomes |
Non-Patent Citations (2)
Title |
---|
LINARES-ALBA ET AL.: "Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease", 《JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS》 * |
MISHRA ET AL.: "Recent Applications of Liposomes in Ophthalmic Drug Delivery", 《JOURNAL OF DRUG DELIVERY》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019513807A (ja) | 2019-05-30 |
EP3445334A4 (en) | 2019-12-25 |
CN109310634B (zh) | 2022-05-31 |
US11672784B2 (en) | 2023-06-13 |
EP3445334A1 (en) | 2019-02-27 |
WO2017184080A1 (en) | 2017-10-26 |
JP7186093B2 (ja) | 2022-12-08 |
US20230263780A1 (en) | 2023-08-24 |
SG10202010303UA (en) | 2020-11-27 |
SG11201809154UA (en) | 2018-11-29 |
US20190117631A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Elnaggar et al. | Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate | |
Li et al. | Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery | |
Bendas et al. | Enhanced transdermal delivery of salbutamol sulfate via ethosomes | |
El-Nabarawi et al. | Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability | |
Firthouse et al. | Formulation and evaluation of miconazole niosomes | |
CN110505869A (zh) | 脂质体组合物及医药组合物 | |
Ibrahim et al. | Once daily pregabalin eye drops for management of glaucoma | |
US10646442B2 (en) | Liposome composition and method for producing same | |
EP3138558B1 (en) | Liposome composition and production method therefor | |
US20190336447A1 (en) | Liposome composition and method for producing same | |
CN102302447B (zh) | 一种新型紫杉醇脂质微球注射液及其制备方法 | |
Wang et al. | A novel phytantriol-based lyotropic liquid crystalline gel for efficient ophthalmic delivery of pilocarpine nitrate | |
JP2008542402A (ja) | ナノ粒子被覆カプセルの乾燥製剤 | |
CN102366411B (zh) | 一种地塞米松棕榈酸酯脂质体注射液 | |
CN102366408A (zh) | 单唾液酸四己糖神经节苷脂钠脂质体注射剂 | |
CN109310634A (zh) | 用于治疗前段眼部疾病的持续输送他克莫司的纳米脂质体 | |
JP5920875B2 (ja) | 真菌感染症を治療するための新規な製剤 | |
ES2879860T3 (es) | Composición farmacéutica soluble en agua que comprende al menos una sustancia terapéuticamente activa con propiedades hidrofóbicas y al menos un compuesto seleccionado entre los sialoglicoesfingolípidos, y una mezcla de sialoglicoesfingolípidos y glicoesfingolípidos | |
Charumathy et al. | Recent update on liposome-based drug delivery system | |
CN103040751B (zh) | 一种细辛脑脂质体注射剂 | |
Sivathanu et al. | Formulation, Characterization and In vitro Drug Delivery of Vitexin Loaded Liposomes | |
CN103040744B (zh) | 一种棓丙酯脂质体注射剂 | |
CN102716081B (zh) | 一种多西紫杉醇囊泡型磷脂凝胶注射液 | |
Nadaf et al. | Novel Liposome Derived Nanoparticulate Drug Delivery System: Fabrication and Prospects | |
Manjula | Development and Evaluation of Membrane Moderated Therapeutic Systems and Liposomal Systems as Carriers for Transdermal Delivery of Few Novel Nsaid’s |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information |
Inventor after: S.Wenkatraman Inventor after: J.V.Natalajan Inventor after: Mei Yanchang Inventor after: J.S.Mehta Inventor after: Huang Siling Inventor after: Huang Xiwen Inventor after: Huang Hequn Inventor before: S.Wenkatraman Inventor before: J.V.Natalajan Inventor before: Mei Yanchang Inventor before: J.S.Mehta Inventor before: Huang Siling Inventor before: Huang Xiwen |
|
CB03 | Change of inventor or designer information | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: S.Wenkatraman Inventor after: J.V.Natarajan Inventor after: Mei Yanchang Inventor after: J.S.Mehta Inventor after: Huang Siling Inventor after: Huang Xiuwen Inventor after: Huang Hequn Inventor before: S.Wenkatraman Inventor before: J.V.Natarajan Inventor before: Mei Yanchang Inventor before: J.S.Mehta Inventor before: Huang Siling Inventor before: Huang Xiwen Inventor before: Huang Hequn |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |